Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | RGS12 | O14924 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | G6PD | P11413 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26098487 | 0.91 | TSHR (0.31) | TSHRALDH1A1RGS12 | |
| SCHEMBL15751172 | 0.78 | CYP2C19 (0.35) | — | |
| SCHEMBL31071615 | 0.77 | G6PD (0.32) | ALDH1A1NPC1G6PD | |
| SCHEMBL14533783 | 0.76 | ALDH1A1 (0.34) | TSHRALDH1A1RGS12NPC1 | |
| SCHEMBL22045518 | 0.73 | TSHR (0.44) | TSHRALDH1A1RGS12NPC1G6PD | |
| SCHEMBL23010719 | 0.73 | POLB (0.33) | NPC1 | |
| SCHEMBL11524932 | 0.71 | RECQL (0.53) | ALDH1A1 | |
| SCHEMBL11043155 | 0.71 | EPHX2 (0.48) | TSHRALDH1A1NPC1 | |
| SCHEMBL11043150 | 0.71 | EPHX2 (0.48) | TSHRALDH1A1NPC1 | |
| SCHEMBL687674 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143165-A1 | SPIROUREA DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2023-03-08 | — | — | EP | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240316020-A1 | Novel Pyridine Compounds | ANGELINI PHARMA S.P.A. (IT) | 2024-09-26 | — | — | US | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20230136562-A1 | SPIROUREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316020-A1 | Novel Pyridine Compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RB1, REN | TSHR 661/4885ALDH1A1 1326/4885RGS12 1301/4885 |
| US-20230136562-A1 | SPIROUREA DERIVATIVES | KCNA7, PKD2, KCNN3 | TSHR 778/4885ALDH1A1 958/4885RGS12 2920/4885 |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | TSHR 1815/4885ALDH1A1 2537/4885RGS12 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.